{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:59:55Z","timestamp":1783511995409,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01794-w","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:31:38Z","timestamp":1752139898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The efficacy and safety of venetoclax combined with decitabine in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"25","author":[{"given":"Feng","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukai","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"1794_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.tcb.2022.11.004","volume":"33","author":"G Egan","year":"2023","unstructured":"Egan G, Schimmer AD. Contribution of metabolic abnormalities to acute myeloid leukemia pathogenesis. Trends Cell Biol. 2023;33:455\u201362.","journal-title":"Trends Cell Biol"},{"key":"1794_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, et al. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21:503\u201313.","journal-title":"J Natl Compr Canc Netw"},{"key":"1794_CR3","first-page":"379","volume":"19","author":"JF Yamamoto","year":"2008","unstructured":"Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997\u20132002. Cancer Causes Control. 2008;19:379\u201390.","journal-title":"Cancer Causes Control"},{"key":"1794_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"key":"1794_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ejh.13752","volume":"108","author":"RJ Stubbins","year":"2022","unstructured":"Stubbins RJ, Stamenkovic M, Roy C, Rodrigo J, Chung S, Kuchenbauer FC, et al. Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: real-world outcomes from a population-based cohort. Eur J Haematol. 2022;108:437\u201345.","journal-title":"Eur J Haematol"},{"key":"1794_CR6","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.18632\/oncotarget.23629","volume":"9","author":"SH Shin","year":"2018","unstructured":"Shin SH, Cho BS, Park SS, Cho SY, Jeon YW, Yoon JH, et al. Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy. Oncotarget. 2018;9:5823\u201333.","journal-title":"Oncotarget"},{"key":"1794_CR7","first-page":"5","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5\u201329.","journal-title":"CA Cancer J Clin"},{"key":"1794_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40258-013-0032-2","volume":"11","author":"J Meyers","year":"2013","unstructured":"Meyers J, Yu Y, Kaye JA, Davis KL. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 2013;11:275\u201386.","journal-title":"Appl Health Econ Health Policy"},{"key":"1794_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11864-017-0445-5","volume":"18","author":"X Thomas","year":"2017","unstructured":"Thomas X, Le Jeune C. Treatment of elderly patients with acute myeloid leukemia. Curr Treat Options Oncol. 2017;18:2.","journal-title":"Curr Treat Options Oncol"},{"key":"1794_CR10","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Ravandi F, O\u2019Brien S, Cortes J, Faderl S, Garcia-Manero G, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116:4422\u20139.","journal-title":"Blood"},{"key":"1794_CR11","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/S0140-6736(10)62105-8","volume":"376","author":"U Krug","year":"2010","unstructured":"Krug U, R\u00f6llig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376:2000\u20138.","journal-title":"Lancet"},{"key":"1794_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/943823","volume":"2010","author":"LD Eleni","year":"2010","unstructured":"Eleni LD, Nicholas ZC, Alexandros S. Challenges in treating older patients with acute myeloid leukemia. J Oncol. 2010;2010: 2010:943823.","journal-title":"J Oncol"},{"key":"1794_CR13","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, M\u00f6llg\u00e5rd L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179\u201387.","journal-title":"Blood"},{"key":"1794_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.blre.2016.09.005","volume":"31","author":"NA Podoltsev","year":"2017","unstructured":"Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2017;31:43\u201362.","journal-title":"Blood Rev"},{"key":"1794_CR15","doi-asserted-by":"publisher","first-page":"41498","DOI":"10.18632\/oncotarget.17241","volume":"8","author":"PF He","year":"2017","unstructured":"He PF, Zhou JD, Yao DM, Ma JC, Wen XM, Zhang ZH, et al. Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Oncotarget. 2017;8:41498\u2013507.","journal-title":"Oncotarget"},{"key":"1794_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.06.004","volume":"19","author":"MR Bian","year":"2019","unstructured":"Bian MR, Yang HS, Lin GQ, Wan Y, Wang L, Si YJ, et al. Decitabine compared with conventional regimens in older patients with acute myeloid leukemia: a meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19: e636\u2013e48.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1794_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/MOH.0000000000000400","volume":"25","author":"G Montalban-Bravo","year":"2018","unstructured":"Montalban-Bravo G, Garcia-Manero G, Jabbour E. Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. Curr Opin Hematol. 2018;25:146\u201353.","journal-title":"Curr Opin Hematol"},{"key":"1794_CR18","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670\u20137.","journal-title":"J Clin Oncol"},{"key":"1794_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41408-022-00770-x","volume":"12","author":"D Kwag","year":"2022","unstructured":"Kwag D, Cho BS, Bang SY, Lee JH, Min GJ, Park SS, et al. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer J. 2022;12:169.","journal-title":"Blood Cancer J"},{"key":"1794_CR20","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317.","journal-title":"Cancer Discov"},{"key":"1794_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","volume":"132","author":"M Konopleva","year":"2018","unstructured":"Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood. 2018;132:1007\u201312.","journal-title":"Blood"},{"key":"1794_CR22","unstructured":"FDA approves venetoclax in combination for AML in adults. 2018. 12. 14. https:\/\/www.fda.gov\/drugs\/fda-approves-venetoclax-combination-aml-adults."},{"key":"1794_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"1794_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"key":"1794_CR25","first-page":"120","volume":"17","author":"AZ Chen","year":"2024","unstructured":"Chen AZ, Wang MJ, Ma XM. Comparison of azacitidine and decitabine in combination with venetoclax in the treatment of elderly patients with acute myeloid leukemia. Chin J Clin Rational Drug Use. 2024;17:120\u20133.","journal-title":"Chin J Clin Rational Drug Use"},{"key":"1794_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.26061","volume":"96","author":"A Maiti","year":"2021","unstructured":"Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, et al. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021;96:282\u201391.","journal-title":"Am J Hematol"},{"key":"1794_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021;96:208\u201317.","journal-title":"Am J Hematol"},{"key":"1794_CR28","first-page":"182","volume":"41","author":"YL Ren","year":"2019","unstructured":"Ren YL, Ma YP, Li XJ, Wang XY. Analysis of the efficacy of Venegra combined with decitabine in the treatment of relapsed acute myeloid leukemia in elderly people. Chin Health Care. 2019;41:182\u20135.","journal-title":"Chin Health Care"},{"key":"1794_CR29","first-page":"1061","volume":"15","author":"SJ Zhang","year":"2022","unstructured":"Zhang SJ, Xu XX, Tang YY. Comparison of the clinical efficacy of decitabine combined with venetoclax and decitabine combined with CAG regime in treatment of elderly patients with newly treated acute myeloid leukemia. Chin J New Clin Med. 2022;15:1061\u20136.","journal-title":"Chin J New Clin Med"},{"key":"1794_CR30","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","volume":"3","author":"DA Pollyea","year":"2019","unstructured":"Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3:4326\u201335.","journal-title":"Blood Adv"},{"key":"1794_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.htct.2018.09.001","volume":"41","author":"EDV Campos","year":"2019","unstructured":"Campos EDV, Pinto R. Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia. Hematol Transfus Cell Ther. 2019;41:169\u201377.","journal-title":"Hematol Transfus Cell Ther"},{"key":"1794_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719882822","volume":"10","author":"G Richard-Carpentier","year":"2019","unstructured":"Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol. 2019;10: 2040620719882822.","journal-title":"Ther Adv Hematol"},{"key":"1794_CR33","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/ajh.25978","volume":"95","author":"E Morsia","year":"2020","unstructured":"Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95:1511\u201321.","journal-title":"Am J Hematol"},{"key":"1794_CR34","first-page":"1837","volume":"28","author":"MY Wei","year":"2024","unstructured":"Wei MY, Yin J, Liao Y, Liu JY, Zhao Y, Chen XM, et al. The efficacy and safety of venetoclax combined with demethylating agents in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2024;28:1837\u201346.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1794_CR35","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","volume":"37","author":"E Jahn","year":"2023","unstructured":"Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L, et al. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia. 2023;37:2187\u201396.","journal-title":"Leukemia"},{"key":"1794_CR36","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","volume":"133","author":"G Huls","year":"2019","unstructured":"Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133:1457\u201364.","journal-title":"Blood"},{"key":"1794_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.leukres.2018.02.002","volume":"68","author":"BC Medeiros","year":"2018","unstructured":"Medeiros BC. Interpretation of clinical endpoints in trials of acute myeloid leukemia. Leuk Res. 2018;68:32\u20139.","journal-title":"Leuk Res"},{"key":"1794_CR38","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.7150\/jca.18686","volume":"8","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, Mangal N, Menon RM, Freise KJ, Salem AH. Response rates as predictors of overall survival: a meta-analysis of acute myeloid leukemia trials. J Cancer. 2017;8:1562\u20137.","journal-title":"J Cancer"},{"key":"1794_CR39","unstructured":"FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia. 2020. 10. 16. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia."}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01794-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:51:33Z","timestamp":1764917493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01794-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1794"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01794-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is a meta-analysis. The data comes from published articles and does not require ethical approval and written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"239"}}